Erratum: Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease
- PMID: 28586341
- DOI: 10.1038/nm0617-788d
Erratum: Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease
Erratum for
-
Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease.Nat Med. 2017 May;23(5):579-589. doi: 10.1038/nm.4307. Epub 2017 Apr 3. Nat Med. 2017. PMID: 28368383 Free PMC article.
Similar articles
-
Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease.Nat Med. 2017 May;23(5):579-589. doi: 10.1038/nm.4307. Epub 2017 Apr 3. Nat Med. 2017. PMID: 28368383 Free PMC article.
-
Oncostatin M Induces a Pro-inflammatory Phenotype in Intestinal Subepithelial Myofibroblasts.Inflamm Bowel Dis. 2024 Nov 4;30(11):2162-2173. doi: 10.1093/ibd/izae098. Inflamm Bowel Dis. 2024. PMID: 38717842
-
Serum oncostatin M predicts mucosal healing in patients with inflammatory bowel diseases treated with anti-TNF, but not vedolizumab.Dig Liver Dis. 2022 Oct;54(10):1367-1373. doi: 10.1016/j.dld.2022.03.008. Epub 2022 Apr 4. Dig Liver Dis. 2022. PMID: 35393259
-
Oncostatin M as a new diagnostic, prognostic and therapeutic target in inflammatory bowel disease (IBD).Expert Opin Ther Targets. 2019 Nov;23(11):943-954. doi: 10.1080/14728222.2019.1677608. Epub 2019 Oct 15. Expert Opin Ther Targets. 2019. PMID: 31587593 Review.
-
Study of tumor necrosis factor receptor in the inflammatory bowel disease.World J Gastroenterol. 2023 May 14;29(18):2733-2746. doi: 10.3748/wjg.v29.i18.2733. World J Gastroenterol. 2023. PMID: 37274062 Free PMC article. Review.
Cited by
-
Putative biomarkers of vedolizumab resistance and underlying inflammatory pathways involved in IBD.BMJ Open Gastroenterol. 2018 May 31;5(1):e000208. doi: 10.1136/bmjgast-2018-000208. eCollection 2018. BMJ Open Gastroenterol. 2018. PMID: 29915667 Free PMC article.
-
Efficacy of JAK1/2 inhibition in murine myeloproliferative neoplasms is not mediated by targeting oncogenic signaling.Nat Commun. 2025 May 24;16(1):4833. doi: 10.1038/s41467-025-60019-6. Nat Commun. 2025. PMID: 40413183 Free PMC article.
-
Alterations and Potential Applications of Gut Microbiota in Biological Therapy for Inflammatory Bowel Diseases.Front Pharmacol. 2022 Jun 6;13:906419. doi: 10.3389/fphar.2022.906419. eCollection 2022. Front Pharmacol. 2022. PMID: 35734396 Free PMC article. Review.
-
The Gut Microbiota Affects Anti-TNF Responsiveness by Activating the NAD+ Salvage Pathway in Ulcerative Colitis.Adv Sci (Weinh). 2025 Feb;12(8):e2413128. doi: 10.1002/advs.202413128. Epub 2024 Dec 30. Adv Sci (Weinh). 2025. PMID: 39739648 Free PMC article.
-
New Frontiers in Genetics, Gut Microbiota, and Immunity: A Rosetta Stone for the Pathogenesis of Inflammatory Bowel Disease.Biomed Res Int. 2017;2017:8201672. doi: 10.1155/2017/8201672. Epub 2017 Aug 2. Biomed Res Int. 2017. PMID: 28831399 Free PMC article. Review.
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources